Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 13 of 13

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2013

Clinical outcomes and prognostic factors associated with Acanthamoeba keratitis treated with pentamidine isethionate

Jane Huang; Hiroaki Ozaki; Naoyasu Umeda; Aki Fuchigami; Masahiko Kozawa; Eiichi Uchio

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):879.

ARVO Annual Meeting Abstract April 2009

Incidence and Outcome of Endophthalmitis After Pars Plana Vitrectomy

H. Ozaki; J. Y. Huang; M. Kozawa; N. Umeda; N. Arita; H. Migita; H. Kondo; H. Hayashi; E. Uchio

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):3562.

ARVO Annual Meeting Abstract May 2008

ATN-224.021 and ATN-427.021 Suppress Choroidal Neovascularization

S. Kachi; N. Umeda; H. Akiyama; M. Kachi; S. F. Hackett; A. P. Mazar; P. A. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):3426.

ARVO Annual Meeting Abstract May 2007

Delayed-Onset Endophthalmitis Caused by Fusarium After Cataract Surgery

N. Umeda; H. Ozaki; K. Murata; A. Yamaguchi; E. Uchio

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):684.

ARVO Annual Meeting Abstract May 2006

Topical Administration of Tg100801, a Multi–Targeted Tyrosine Kinase Prodrug, Inhibits Choroidal Neovascularization in Mice

J. Hood; N. Umeda; P. Campochiaro; S. Yee; K. Barrett; G. Noronha; R. Soll

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5184.

ARVO Annual Meeting Abstract May 2006

Suppression and Regression of Choroidal Neovascularization by Systemic Administration of an 5ß1 Integrin Antagonist

N. Umeda; S. Kachi; H. Akiyama; G. Zahn; R. Stragies; P.A. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):899.

ARVO Annual Meeting Abstract May 2006

Delivery of Angioinhibitory Genes Using the VMD2 Promoter in Lentiviral Vectors Results in Selective Expression in RPE and Inhibition of Choroidal Neovascularization

S. Kachi; K. Binley; N. Umeda; H. Akiyama; K. Yokoi; M. Kachi; W. Xiao; M. Espa; S. Naylor; P.A. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):906.

ARVO Annual Meeting Abstract May 2006

Development of an EIAV Lentiviral Based Gene Therapy, RetinoStat®, for the Treatment of CNV Age–Related Macular Degeneration

K.M. Binley; S. Kachi; N. Umeda; H. Akiyama; K. Yokoi; W. Xiao; M. Kachi; S. Iqball; S. Naylor; P. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):908.

ARVO Annual Meeting Abstract May 2006

Engineered Zinc Finger Protein Transcription factors as a Potential Therapy for Ocular Neovascularization

H.S. Zhang; S. Kachi; M. Kachi; P.–Q. Liu; H. Akiyama; N. Umeda; K. Yokoi; S. Hackett; P.D. Gregory; P.A. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1786.

ARVO Annual Meeting Abstract May 2005

A VEGF121–Gelonin Fusion Protein (VEGF121/rGel) Induces Regression of Subretinal and Choroidal Neovascularization (CNV)

H. Akiyama; R.L. Silva; S. Kachi; N. Umeda; S. Aslam; S.F. Hackett; K. Mohamedali; M.G. Rosenblum; P.A. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):455.

ARVO Annual Meeting Abstract May 2005

Vascular Endothelial Growth Factor Level in Stage5 Retinopathy of Prematurity

H. Ozaki; N. Umeda; T. Shitama; H. Hayashi; K. Oshima

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):4128.

ARVO Annual Meeting Abstract May 2005

Angiopoietin 1 Prevents Retinal Detachment in an Aggressive Model of Proliferative Retinopathy, but Has No Effect on Established Neovascularization

N. Umeda; H. Nambu; S. Kachi; Y. Oshima; H. Akiyama; R. Nambu; P.A. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):4193.

ARVO Annual Meeting Abstract May 2003

Increased Soluble Interleukin-6 Receptor in Vitreous Fluid of Proliferative Vitreoretinopathy

H. Yamamoto; H. Hayashi; H. Uchida; N. Umeda; H. Ozaki; H. Kato; K. Oshima

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):2953.

Advertisement